Clinical Trials

The primary objective of this registry is to obtain long-term survivorship data for the use of fresh OCAs in cartilage repair and reconstruction procedures.

The purpose of this study is to test the safety of this novel cell, combination- based regenerative therapy for use in patients with symptomatic focal cartilage defects of the knee.

The primary objective of the study is to assess the local and systemic safety of a single operative application of autologous chondrons mixed with culture expanded allogeneic AMSCs (RECLAIM) in the treatment of symptomatic focal cartilage defects of the hip.

The secondary objectives of the study are to assess the effect of RECLAIM on pain and function in the target hip, and to assess the effect of RECLAIM on bone and cartilage structures within the target hip using MRI.

The purpose of this research study is to gather information on the safety and effectiveness of Autologous Chondrocyte Transplantation system, Novocart® 3D, in comparison to standard microfracture treatment for injured knee.

This study will evaluate the bio-mechanical and biochemical abnormalities in acute ACL-injured knees over time. Data will be collected through advanced quantitative MR imaging, functional testing, and bio-specimen collection. Researchers will collect this data from the time of baseline visit, which is within 28 days of injury, through the temporal sequence of post-operative or post-injury recovery and return to activity.

The hypotheses for this study are (1) that T1ρ and T2 will be significantly elevated in the lateral side of ACL-injured knees immediately after injury (indicating damage caused by initial injury), and will not fully recover at 6-month, 1-year ...

This confirmatory study is a prospective randomized trial comparing the efficacy and safety of an autologous chondrocyte tissue implant (NeoCart) to the surgical intervention microfracture in the treatment of cartilage defects in the knee.

The purpose of this study is to gather clinical outcomes data and imaging for patients who are receiving Cartiform for articular cartilage defects as a standard of care treatment.                                           

The goals of this continuation of MeTeOR are to determine: a) whether the greater structural damage observed at five years in subjects treated with APM persists over 12 years; and b) whether structural changes observed in the first five years are associated with worse pain and function and greater TKR utilization at 12 years. We propose the following aims:

1. Conduct a 12-year follow-up visit of MeTeOR subjects to characterize the extent of cartilage damage over 12 years and identify factors associated with OA progression. MeTeOR participants will complete questionnaires and performance tests and undergo MRI and radiographs 12 years ...